Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An update from Wuxi Biologics (Cayman) ( (HK:2269) ) is now available.
WuXi Biologics has announced a significant increase in its financial performance for the first half of 2025, with a 16% rise in revenue and a 54% increase in profit. This growth is attributed to the company’s strategic execution, expanded service offerings, and efficiency improvements, highlighting its strong positioning in the biologics industry.
The most recent analyst rating on (HK:2269) stock is a Hold with a HK$23.40 price target. To see the full list of analyst forecasts on Wuxi Biologics (Cayman) stock, see the HK:2269 Stock Forecast page.
More about Wuxi Biologics (Cayman)
WuXi Biologics (Cayman) Inc. is a prominent player in the biologics industry, offering a wide range of services including discovery, pre-IND development, clinical, and commercial manufacturing. The company is known for its advanced technology platforms, such as ADC and Bispecific Antibodies, and has a strong market focus on expanding its service spectrum and utilizing cutting-edge technologies.
Average Trading Volume: 43,277,027
Technical Sentiment Signal: Buy
Current Market Cap: HK$113.9B
See more insights into 2269 stock on TipRanks’ Stock Analysis page.